As per the research report, the size of the Europe Erythropoietin Drugs Market was valued at USD 3.39 billion in 2020 and estimated to be growing at a CAGR of 9.5%, to reach USD 5.33 billion by 2025 during the forecast period 2020-2025.
Erythropoietin is present in the bone marrow cells controlling the production of red blood cells. They can be used for the treatment of anaemia, HIV and Cancer. Various synthetic forms of erythropoietin are available in the market due to advancements in recombinant DNA technology.
Increased incidence of anaemia, rising commercialisation of EPO drugs and favourable reimbursement policies are further driving the market growth. As cheaper biosimilars are also available the market is expected to propel during the forecast period.
This research report segmented and sub-segmented into the following categories:
The Erythropoietin Drugs market was dominated by Europe.
Key players operating in the Europe Erythropoietin Drugs Market profiled in this report are Johnson & Johnson, Celltrion, Inc, Teva Pharmaceutical Industries Ltd. , Sun Pharmaceutical Industries Ltd. , Dr. Reddy’s Laboratories Ltd.Amgen, Inc. , F. Hoffmann-La Roche Ltd. , LG Life Sciences Ltd. , Biocon Limited and Intas Pharmaceuticals Ltd.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Epoetin-alfa
5.1.3 Epoetin-beta
5.1.4 Darbepoetin-alfa
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Application
5.2.1 Introduction
5.2.2 Cancer
5.2.3 Hematology
5.2.4 Renal diseases
5.2.5 Y-o-Y Growth Analysis, By application
5.2.6 Market Attractiveness Analysis, By application
5.2.7 Market Share Analysis, By application
5.3 Drug class
5.3.1 Introduction
5.3.2 Biologics
5.3.3 Biosimilars
5.3.4 Y-o-Y Growth Analysis, By drug class
5.3.5 Market Attractiveness Analysis, By drug class
5.3.6 Market Share Analysis, By drug class
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By application
6.1.3.4 By drug class
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By application
6.1.4.4 By drug class
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By application
6.1.5.4 By drug class
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Johnson & Johnson
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Celltrion, Inc.
8.3 Teva Pharmaceutical Industries Ltd.
8.4 Amgen, Inc.
8.5 F. Hoffmann-La Roche Ltd.
8.6 LG Life Sciences Ltd.
8.7 Biocon Limited
8.8 Intas Pharmaceuticals Ltd.
8.9 Sun Pharmaceutical Industries Ltd.
8.10 Dr. Reddy’s Laboratories Ltd.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
